Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia · 2020
The effect of folate and VitB12 in the treatment of MCI patients with hyperhomocysteinemia.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jiang Bo, Yao Guoen, Yao Cunshan, Zheng Na
Аннотация
OBJECTIVE: This study aims to investigate the effect of folate combined with VitB12 on serum total homocysteine (tHcy) levels and cognitive function in patients with mild cognitive impairment (MCI) complicated by hyperhomocysteinemia (HHcy).
METHODS: (1) A total of 92 MCI patients with HHcy were enrolled in this study and randomly divided into two groups: the intervention group (46 cases) and the control group (46 cases). (2) The patients in both groups received the routine treatment for their condition, but patients in the intervention group were also given 5 mg/day of folate and 500 μg × 3/day of VitB12. (3) The changes in levels of folate, VitB12, and tHcy, the Montreal Cognitive Assessment (MoCA) score and the event-related potential (P300) were observed before and after treatment.
RESULTS: (1) There were no statistically significant differences in folate, VitB12, and tHcy levels, the MoCA score and the P300 between the two groups before treatment. (2) At the 4th, 12th and 24th week, folate and VitB12 levels in the intervention group were higher than those in the same group before treatment and those in the control group at the same time points, while tHcy levels were lower than those in the same group before treatment and those in the control group at the same time points. (3) At the 24th week, the MoCA score in the control group was lower than before treatment, and the MoCA score in the intervention group was higher than in the same group before treatment and in the control group at the same time point. The P300 latency was shorter than it was in the same group before treatment and in the control group at the same time point.
CONCLUSION: Folate and VitB12 can effectively reduce levels of tHcy in patients with MCI and improve cognitive function.
METHODS: (1) A total of 92 MCI patients with HHcy were enrolled in this study and randomly divided into two groups: the intervention group (46 cases) and the control group (46 cases). (2) The patients in both groups received the routine treatment for their condition, but patients in the intervention group were also given 5 mg/day of folate and 500 μg × 3/day of VitB12. (3) The changes in levels of folate, VitB12, and tHcy, the Montreal Cognitive Assessment (MoCA) score and the event-related potential (P300) were observed before and after treatment.
RESULTS: (1) There were no statistically significant differences in folate, VitB12, and tHcy levels, the MoCA score and the P300 between the two groups before treatment. (2) At the 4th, 12th and 24th week, folate and VitB12 levels in the intervention group were higher than those in the same group before treatment and those in the control group at the same time points, while tHcy levels were lower than those in the same group before treatment and those in the control group at the same time points. (3) At the 24th week, the MoCA score in the control group was lower than before treatment, and the MoCA score in the intervention group was higher than in the same group before treatment and in the control group at the same time point. The P300 latency was shorter than it was in the same group before treatment and in the control group at the same time point.
CONCLUSION: Folate and VitB12 can effectively reduce levels of tHcy in patients with MCI and improve cognitive function.